AMGN - Amgen Inc.
| Previous Close | 191.56 |
| Open | 192.91 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 100 |
| Day's Range | 191.04 - 194.82 |
| 52 Week Range | 163.31 - 210.19 |
| Volume | 1,889,802 |
| Avg. Volume | 2,689,596 |
| Market Cap | 122.059B |
| Beta (3Y Monthly) | 1.36 |
| PE Ratio (TTM) | 59.71 |
| EPS (TTM) | 3.21 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 5.28 (2.73%) |
| Ex-Dividend Date | 2018-11-15 |
| 1y Target Est | 204.25 |
- GuruFocus.com•12 hours ago
Despite Lofty Price, Illumina May Still Be a Buy
The company already had a dominant position in the fast-growing gene sequencing market before strengthening its position with the acquisition of Pacific Biosciences
Markit•18 hours agoSee what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
- Reuters•19 hours ago
Express Scripts offers new formulary for lower list-price drugs
Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients. Drug rebates have come under fire from the Trump Administration and consumer groups as patients find themselves paying much higher insurance co-payments and deductibles tied to a drug's sticker price.
- Zacks•yesterday
Amgen (AMGN) Stock Moves -0.83%: What You Should Know
Amgen (AMGN) closed the most recent trading day at $191.56, moving -0.83% from the previous trading session.
- PR Newswire•yesterday
Amgen Presents Results Highlighting The Long-Term Safety And Efficacy Of Repatha® (Evolocumab) In The Longest Duration Study Of A PCSK9 Inhibitor To Date At AHA Scientific Sessions 2018
THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (AMGN) today announced the final report of the Open-Label Study of Long-TERm Evaluation Against LDL-C (OSLER-1), demonstrating long-term treatment with Repatha® (evolocumab) was associated with robust and consistent reductions in low-density lipoprotein cholesterol (LDL-C), with no increase in overall rates of adverse events over time and no neutralizing antibodies. Additionally, data from the Getting to an ImprOved Understanding of Low-Density Lipoprotein and Dyslipidemia Management (GOULD) Registry reflect a disconnect between physician perception of lipid-lowering therapies (LLTs) and their actual use, and highlight both a need for improved patient awareness of the goals of LLT and a need to address barriers to use of medications like Repatha.
- TheStreet.com•yesterday
Amgen Is Showing Independent Strength in a Bullish Sign for the Future
Mad Money viewers Friday night got a long recommendation from Jim Cramer. Cramer said to look no further than drug maker Amgen Inc. Cramer said that Amgen is a well-run company with a solid balance sheet that includes $42 billion in cash.
- Zacks•2 days ago
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
- PR Newswire•2 days ago
Amgen Foundation Pledges $500,000 In Relief To Victims Of Ventura And Los Angeles County Wildfires
THOUSAND OAKS, Calif., Nov. 12, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the local wildfires in Ventura and Los Angeles Counties. The Amgen Foundation will select recipient non-profit organizations based on relief effort needs. In addition, the Amgen Foundation has committed $250,000 to the Ventura County Community Foundation's Conejo Valley Victims Fund to support the victims, families and organizations providing support after the recent Thousand Oaks shooting tragedy.
- CNBC•2 days ago
Investors are flocking to 'quality' stocks. Here's what that means for the market
A grouping of such companies by Citi surfaced the likes of Walmart, McDonald's, Pfizer, Procter & Gamble, Amgen and Quest Diagnostics. While not predictive in itself, this pattern is one seen in the run-up to a bear market. Shares of quality companies have been outperforming the broad benchmarks — both before the October market correction and on the bounce of the past two weeks.
- Motley Fool•3 days ago
Better Buy: Amgen Inc. vs. Pfizer Inc.
Which big drugmaker is the better pick for long-term investors?
Markit•4 days agoSee what the IHS Markit Score report has to say about Amgen Inc.
Amgen Inc NASDAQ/NGS:AMGN
- CNBC•4 days ago
Cramer Remix: Next week's earnings could make or break how the Fed approaches rate hikes
CNBC's Jim Cramer explains how a strong consumer snapshot could force an ugly reaction from the Fed. The "Mad Money" host also hears from the CEO of Funko, a company that makes popular big-headed dolls. In the lightning round, Cramer says the Fed has curbed his enthusiasm on some stocks.
- Investor's Business Daily•5 days ago
Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018
Repligen stock is on a rampage this year as it outperforms broad medical-products stocks. The bioprocessing firm has completely transformed, its CEO says.
- InvestorPlace•5 days ago
6 Pharmaceutical Stocks to Buy After the Midterms
Despite massive gains for the Democrats in the midterm elections in the House of Representatives and on the state level, the Republicans managed to hold onto the Senate. This is good for big pharmaceutical stocks (if bad for pharmaceutical users). Had the Democrats won both the House and Senate, scrutiny over drug pricing and the actions of the largest pharmaceutical companies would have resumed.
Market Realist•5 days agoHow Analysts View Alexion Stock
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.
Market Realist•5 days agoAnalyzing Alexion Pharmaceuticals’ Dicerna Collaboration
In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.
Associated Press•5 days agoThe Latest: Calif. shooting survivor was at Vegas massacre
THOUSAND OAKS, Calif. (AP) — The Latest on the shooting at a Southern California bar that left 13 dead including the gunman (all times local):
- Reuters•5 days ago
Coherus prices biosimilar to Amgen's Neulasta at 33 pct discount
Coherus BioSciences Inc said on Thursday it would price its biosimilar to Amgen Inc's infection-fighting treatment, Neulasta, at a 33 percent discount. The list price of $4,175 per unit set by Coherus is the same as Mylan NV's biosimilar Fulphila that was approved earlier this year. Coherus intends to launch the biosimilar, Udenyca, on Jan. 3, it said on a conference call.
Market Realist•6 days agoA Look at Alexion Pharmaceuticals’ Operational Performance
For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.
Market Realist•6 days agoAnalyzing Alexion Pharmaceuticals’ Product Performance
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.
Market Realist•6 days agoHow Alexion Is Positioned in November
Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.
- Motley Fool•6 days ago
Here's Why bluebird bio Fell 21.4% in October
In September and October, investors thought Amgen set the bar in multiple myeloma too high, but in November bluebird bio teased promising data of its own.
InvestorPlace•6 days ago7 Healthcare Stocks Soaring on Election Results
The company will next report results on Feb. 1 before the bell. Analysts are looking for earnings of $1.05 per share on revenues of $10.99 billion. When the company last reported on Oct. 25 earnings of $1.19 per share beat estimates by five cents on a 4.5% rise in revenues.
- Investing.com•7 days ago
Amgen Rises 3%
Investing.com - Amgen (NASDAQ:AMGN) rose by 3.06% to trade at $196.59 by 11:45 (16:45 GMT) on Wednesday on the NASDAQ exchange.
- TheStreet.com•7 days ago
Drug Stocks Climb as Investors Digest Midterm Election Results
Tuesday's midterm election results were welcome news for Big Pharma. Drug stocks rose on Wednesday, Nov. 7 amid perceptions that a divided Congress makes it less likely for major changes to occur in the drug-pricing environment in the U.S., analysts said. "Though we didn't view last night's outcome as removing all political risk to the group, it should make it more difficult to enact any major changes to the drug-pricing regime in America (which was already unlikely) and help improve investor sentiment, especially for the larger-caps," wrote biotech analysts at RBC Capital Markets LLC in a Wednesday note.
